NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

The firms will partner to carry out experiments that seek to identify cancer genome targets. H3 will carry out early target discovery through pre-clinical research, and Horizon will use its drug discovery tools "to run alongside and support [H3's] discovery biology and chemistry assets and capabilities," the partners said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.